PROGRAM

The 2nd Congress of the Macedonian Hematology Association with International Participation

18 April 2017 (Tuesday)

Time   Lecture Lecturer
09:00-09:30

Opening of the Congress

SESSION 1: Updates on acute leukemia's and myelodisplastic syndromes 

Chairs: Lidija Cevreska, Hagop Kantarjian

Time  
09:30-11:35  
09:30-10:05 Lecture 1 Recent advances in AML Farhad Ravandi-Kashani, USA
10:05-10:40 Lecture 2 Recent advances in MDS Elias Jabbour, USA
10:40-11:15 Lecture 3 Recent advances in ALL Hagop M. Kantarjian, USA
11:15-11:35 Coffee break

SESSION 2: Updates on myeloproliferative disorders

Chairs: Irina Panovska, Ellias Jabbour

Time  
11:35-13:20  
11:35-12:10 Lecture 1 Recent advances in CML Elias Jabbour, USA
12:10-12:45 Lecture 2 Molecular Diagnostics and Pathogenesis of Myeloproliferative Neoplasms (MPNs) Sylvie Heurmouet, France
12:45-13:20 Lecture 3 Recent advances in the Classification and treatment of myeloproliferative neoplasms (MPNs) Mary Francys McMulin, Ireland
13:20-14:20 Lunch break

SESSION 3: Updates in laboratory hematology

Chairs: Ivanovski Martin, Oliver Karanfilski

Time  
14:20-15:20  
14:20-14:50 Lecture 1 Flagship and hardship: minimal residual disease detection by flow cytometry Janos Kappelmayer, Hungary
14:50-15:20 Lecture 2 A novel, digital image-based system for Complete Blood Count and WBC Differential counting Milenko Tanasijevic, USA

SESSION 4: Updates on myeloma and lymphoma

Chairs: Urban Novak, Aleksandar Stojanovik

Time  
15:20-17:40  
15:20-15:55 Lecture 1 Indolent lymphomas: curative or palliative approach? Urban Novak, Switzerland
15:55-16:30 Lecture 2 Recent advances in treatment of Hodgkin's lymphoma Igor Aurer, Croatia
16:30-17:05 Lecture 3 Aggressive lymphomas: the WHO classification update and its clinical consequences Urban Novak, Switzerland
17:05-17:40 Lecture 4 The immune checkpoint network in the bone marrow of myeloma patients: lessons from Vgamma9Vdelta2 T cells Massimo Massaia, Italy
17:40-18:00 Coffee break

SESSION 5 Workshop: Updates on CLL

Chairs: Efremov Dimitar, Kostas Stamatopoulos

Time  
18:00-19:45  
18:00-18:35 Lecture 1 Prognostication in CLL: the art of synthesis Kostas Stamatopoulos, Greece
18:35-19:10 Lecture 2 Current therapeutic options in CLL Luca Laurenti, Italy
19:10-19:45 Lecture 3 Novel targeted therapies in CLL: mechanisms of action and resistance Dimitar Efremov, Italy
20:00-21:30   OPENING CEREMONY/COCKTAIL  

19 April (Wednesday ) 2017

Time   Lecture Lecturer

SESSION 6: Insights in non-malignant hematological disorders 

Chairs: Stankovic Svetlana, Dimovski Aleksandar

Time  
08:45-10:05  
08:45-09:05 Lecture 1 Cancer-associated thrombosis: prevention and treatment Darko Antic, Serbia
09:05-09:25 Lecture 2 Inborn thrombophilia Sasko Petlickovski, Macedonia
09:25-09:45 Lecture 3 Beta Thalassemia Intermedia: from Genotype to Phenotype Dijana Plaseska-Karanfilska, Macedonia
09:45-10:05 Coffee break
10:05-11:05 Novo Noridsk symposium: Life threatening bleeding disorders in haemophilia with inhibitors

SESSION 7: Insights in Bone marrow transplant 

Chairs: Nadezda basara , Aleskandra Pivkova-Veljanovska

Time  
11:05-12:00      
11:05-11:35 Lecture 1 How to prevent relapse after allogeneic stem cell transplantation in acute myeloid leukemia's? Nadezda Basara, Germany
11:35-11:55 Lecture 2 Chronic GVHD and current treatment options Mutlu Arat, Turkey
11:55-12:20 Lecture 3 Bone marrow transplantation experience of University Hospital of Hematology - Sofia Bulgaria Gjorgji Mihajlov, Bulgaria
12:20-13:20 Roche symposium: Improving treatment strategies for FL patients: how to translate novel study data into clinical practice 
13:20-14:00 Lunch break

SESSION 8: Insights in MDS and lymphoma

Chairs: Trajkova Sanja, Marek Trneny

Time  
14:00-15:30  
14:00-14:20 Lecture 1 Myelodysplastic syndromes landscapes and their modifying Rajko Kusec, Croatia
14:20-14:40 Lecture 2 Recent advances in treatment of Mantle cell lymphoma Marek Trneny, Czech Republic
14:40-15:10 Lecture 3 The role of prognostic scores in folicular lymphoma in Rituximab era Biljana Mihaljevic, Serbia
15:10-15:30 Lecture 4 Histological and immunohistochemical study of Malignant Lymphomas in Macedonia: study of 222 cases. Gordana Petrusevska, Macedonia
15:30-16:30 Novartis Myelofibrosis symposium
16:30-17:30 Coffee break + poster session (Chairs: Tatjana Smilevska, Gabriela Kostova, Svetlana Kocheva)

SESSION 9:

Chairs: Stojanovski Zlate, Sonja Genadieva-Stavric

Time  
17:30-18:00  
17:30-17:40 poster 1 Treatment and clinical results in childhood acute myeloid leukemia in Macedonia Kocheva Svetlana, Macedonia
17:40-17:50 poster 2 Elderly patients with AML our treatment experience Biljana Todorova et all.,Slovenia
17:50-18:00 poster 3 Position paper of the Association of Hematologists and Transfusiologists of Federation of Bosnia and Herzegovina on the use of biosimilars Azra Jahic et all, Bosnia and Herzegovina 
18:00-18:10 poster 4 Unclassified Case, probably Peripheral T Cell Lymphoma of cerebellum Janevska Vesna, Macedonia
19:00-20:15 Commercial presentation: Gazyva engineered for superiority
20:30-24:00 Gala dinner

20 April 2017 (THURSDAY)

Time   Lecture Lecturer
09:30-10:30   Celgene-sponsored satellite symposium: Azacitidine in the treatment of MDS and AML  

SESSION 10:Workshop about PET SCEN

Chairs: Emilija Janevik-Ivanovska, Raffaele Giubbini

Time  
10:30-12:15  
10:30-11:05 Lecture 1 “PET/CT in myeloma” Jean-Noel Talbot, France
11:05-11:35 Lecture 2 PET/CT in the management of Lymphomas" Raffaele Giubbini,Italy
11:35-12:10 Lecture 3 Role of radiopharmaceuticals in the diagnosis and treatment of hematological diseases” Emilija Janevik-Ivanovska, Macedonia
12:10-12:30 Coffee break
12:30-13:30 PLIVA/TEVA symposium: Lonquex (lipegfilgrastim): new option for chemotherapy-induced neutropenia
13:30-14:30 Lunch break

SESSION 11: pediatric session

Chairs: Martinova Kata, Janez Jazbec

Time  
14:30-16:00  
14:30-14:50 Lecture 1 Acute Lymphoblastic leukemia in childhood- Prognostic factors Kata Martinova, Macedonia
14:50-15:10 Lecture 2 Late effects of the treatment for childhood cancer Jelena Roganovic, Croatia
15:10-15:30 Lecture 3 Relapsed pediatric acute lymphoblastic leukemia-current strategies and perspectives Janez Jazbec, Slovenia
15:30-15:50 Lecture 4 The influence of TSER(2R/3R) and (G2677T/A) polymorphisms on methotrexate induced toxicities in children with acute lymphoblastic leukemia Biljana Coneska-Jovanova, Macedonia
16:00 Closing of the Congress